A Phase 2, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Subretinal Administration of CNTO 2476 in Subjects With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Sep 2017
At a glance
- Drugs CNTO 2476 (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- Sponsors Janssen Pharmaceutical KK
- 20 Mar 2017 Planned End Date changed from 1 Aug 2022 to 19 Aug 2022.
- 20 Mar 2017 Planned primary completion date changed from 1 Feb 2021 to 20 Feb 2021.
- 20 Mar 2017 Planned initiation date changed from 1 Apr 2018 to 9 Apr 2018.